Stock Price, News, Quote and Profile of ARROWHEAD PHARMACEUTICALS IN(NASDAQ:ARWR) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ARROWHEAD PHARMACEUTICALS IN

NASDAQ:ARWR (5/3/2024, 10:32:05 AM)

24.21

+0.08 (+0.33%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap3.00B

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 525 full-time employees. The firm uses a portfolio of ribonucleic acid (RNA) chemistries and efficient modes of delivery. The Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The firm's pipeline includes ARO-APOC3 for Hypertriglyceridemia; ARO-ANG3 for Dyslipidemia; Olpasiran for Cardiovascular disease; ARO-ENAC2 for Cystic fibrosis; ARO-MUC5AC and ARO-RAGE for Muco-obstructive or inflammatory pulmonary conditions; ARO-MMP7 for Idiopathic pulmonary fibrosis, and GSK-4532990 for Non-alcoholic steatohepatitis (NASH). The company also offers Fazirsiran for lpha-1 antitrypsin deficiency (AATD); JNJ-3989 for Chronic hepatitis B virus; ARO-DUX4 for Facioscapulohumeral muscular dystrophy; HZN-457 for Uncontrolled gout; ARO-PNPLA3 for Non-alcoholic steatohepatitis, and ARO-SOD1 for Amyotrophic lateral sclerosis.